Invention Grant
- Patent Title: CAMK2D antisense oligonucleotides and uses thereof
-
Application No.: US16282138Application Date: 2019-02-21
-
Publication No.: US11058767B2Publication Date: 2021-07-13
- Inventor: Richard E. Olson , Brian R. Anderson , Peter Hagedorn , Marianne Lerbech Jensen , Ivar M. McDonald , Stephen E. Mercer
- Applicant: Bristol-Myers Squibb Company , Roche Innovation Center Copenhagen A/S
- Applicant Address: US NJ Princeton; DK Hørsholm
- Assignee: Bristol-Myers Squibb Company,Roche Innovation Center Copenhagen A/S
- Current Assignee: Bristol-Myers Squibb Company,Roche Innovation Center Copenhagen A/S
- Current Assignee Address: US NJ Princeton; DK Hørsholm
- Agency: Sterne, Kessler, Goldstein & Fox P.L.L.C.
- Agent Ji Eun Kim
- Main IPC: C07H21/02
- IPC: C07H21/02 ; C07H21/04 ; A61K39/395 ; A61K47/54 ; A61K47/64 ; A61K47/60 ; A61P9/12 ; A61P9/04 ; A61K9/00 ; C12N5/074 ; C12N5/077 ; C12N15/113 ; A61K31/713 ; A61K39/00
Abstract:
The present disclosure relates to antisense oligonucleotides, which target CAMK2D mRNA in a cell, leading to reduced expression of CAMK2D protein. Reduction of CAMK2D protein expression is beneficial for the treatment of certain medical disorders, e.g., cardiovascular-related diseases or disorders.
Public/Granted literature
- US20190275148A1 CAMK2D ANTISENSE OLIGONUCLEOTIDES AND USES THEREOF Public/Granted day:2019-09-12
Information query
